Abstract:Recently, mounting evidence suggests that cognitive impairment may accompany traditional neurological diseases, such as neurodegenerative disorders, as well as result from previous infections (COVID-19, influenza). One approach to mitigating the neurological pathological state involves regulating abnormal neural activity. Nevertheless, addressing this issue directly may not always be feasible due to neuronal overexcitation or inadequate stimulation, leading to unfavorable outcomes. Meanwhile, astrocytes adapt their activation levels exclusively to the group of neurons requiring activation, boosting cognitive functions as an example [1]. Optogenetics was employed in this study to selectively stimulate metabotropic astrocyte receptors in acute hippocampal slices of mice with an Alzheimer’s model. The aim was to examine the effect on electrophysiological function of neurons, strength of synaptic contacts ex vivo, and cognitive performance in vivo. Several fundamentally different approaches exist for optogenetic stimulation of cells, including the use of molecular targets such as ionotropic receptors (e.g., ChR2) or metabotropic receptors (e.g., OptoGq). Our studies have shown enhanced activity of hippocampal pyramidal neurons and potentiated field excitatory potentials (fEPSP) following optogenetic activation of astrocytes expressing the metabotropic construct OptoGq. Conversely, the use of ChR2 resulted in an opposite effect [2]. For this reason, all subsequent investigations used a metabotropic construct. Astrocytes are known to respond to external stimuli via intracellular calcium [Ca2+] waves. The propagation of this wave results in the release of D-serine, cytokines, and lactate, subsequently modulating the activity of neurons. The role of astrocytes in regulating the function of NMDA receptors by releasing or removing glutamate from the extracellular environment is critical in modulating neural network excitation. Given the association of astrocytes with the pathogenesis and pathological mechanisms involved in neurodegenerative disorders, controlling their activity becomes a pressing and indispensable aspect of therapy. In the present investigation, optogenetic stimulation of hippocampal astrocytes transduced by AAV5_GfaABC1D_opto-a1AR-EYFP virus (which encodes a Gq-coupled metabotropic receptor) resulted in enhanced electrophysiological activity of hippocampal pyramidal neurons. This was evidenced by increased sEPSC of pyramidal neurons and the potentiation of field excitatory postsynaptic potentials (fEPSP) in the hippocampal region, following light activation of astrocytes [2]. A significant activation of early gene expression (cRel, Arc, Fos, JunB, and Egr1) was detected in hippocampal slices [3]. Additionally, optogenetic activation of the metabotropic receptor during behavioral tests in vivo restored cognitive functions in mice with an Alzheimer’s disease model. The activation of the Gq-coupled metabotropic receptor was found to be a molecular target that promotes positive changes in neuronal functioning at ex vivo and in vivo levels in both wild type mice and a mouse model of Alzheimer’s disease. Expression of OPTO-α1AR in astrocytes could potentially have a beneficial impact on other neuropathological conditions. In the future, alternative less-invasive methods, such as chemogenetics, could be employed to specifically activate astrocytes in distinct brain regions.

Chemogenetic modulation of astrocytes and microglia: State‐of‐the‐art and implications in neuroscience

Chemogenetic analysis of how receptors for short chain fatty acids regulate the gut-brain axis

Glial cells undergo rapid changes following acute chemogenetic manipulation of cortical layer 5 projection neurons

Chemogenetic activation of microglial Gi signaling decreases microglial surveillance and impairs neuronal synchronization

Chemogenetic Tools and their Use in Studies of Neuropsychiatric Disorders

Remotely Controlled Chemomagnetic Modulation of Targeted Neural Circuits

Chemogenetic manipulation of astrocytic activity: Is it possible to reveal the roles of astrocytes?

Perturbing cortical networks: in vivo electrophysiological consequences of pan-neuronal chemogenetic manipulations using deschloroclozapine

Chemogenetic and Optogenetic Manipulations of Microglia in Chronic Pain

Molecular targets for optogenetic stimulation of astrocytes for recovering cognitive functions in neurological complications

Chemogenetic modulation of sensory afferents induces locomotor changes and plasticity after spinal cord injury

Taming microglia: the promise of engineered microglia in treating neurological diseases

Imaging-based chemogenetics for dissecting neural circuits in nonhuman primates.

In situ Chemical Reprogramming of Astrocytes into Neurons: A New Hope for the Treatment of Central Neurodegenerative Diseases?

DREADDed Microglia in Pain: Implications for Spinal Inflammatory Signaling in Male Rats.

Astrocytes modulate extracellular neurotransmitter levels and excitatory neurotransmission in dorsolateral striatum via dopamine D2 receptor signaling

Modulation of human induced neural stem cell-derived dopaminergic neurons by DREADD reveals therapeutic effects on a mouse model of Parkinson's disease

A molecular switch for neuroprotective astrocyte reactivity

Chemogenetic manipulation of CX3CR1 + cells transiently induces hypolocomotion independent of microglia

Astrocyte-Neuron Interactions in Substance Use Disorders

Harnessing nanomedicine for modulating microglial states in the central nervous system disorders: Challenges and opportunities